Arginine and the Arginine-to-ADMA Ratio: What These Nitric Oxide Markers Mean

Written by Dr. Ryan Kneessi, ND

Quick answer: Arginine is the amino acid blood vessels use to make nitric oxide, and the arginine-to-ADMA ratio compares it with ADMA, a natural compound that competes with it. A lower ratio generally suggests less usable arginine for nitric oxide and has been associated with higher cardiovascular risk in cohort studies. Arginine alone is a blunter number than these ratios.

Arginine is an amino acid with an outsized job in the blood vessels. It is the only raw material the endothelial cells lining our arteries use to make nitric oxide, the small signaling molecule that helps vessels relax and keeps their lining healthy. A blood arginine level on its own turns out to be a fairly blunt number, so researchers increasingly look at arginine in context. The arginine-to-ADMA ratio compares arginine with ADMA, a natural compound that competes with it at the nitric oxide enzyme. The global arginine bioavailability ratio compares arginine with ornithine and citrulline, the products of the two main pathways that use it up.

This article is educational. It explains what the marker reflects and how researchers connect it to the deeper mechanisms of aging, so you can have a more informed conversation with your own provider.

What does a low arginine-to-ADMA ratio mean?

A lower arginine-to-ADMA ratio generally means that there is less usable arginine relative to its competitor, which suggests that the nitric oxide enzyme may be working at a disadvantage. In a 2011 study of about 1,140 relatively healthy adults in the Framingham Offspring Cohort, Lüneburg and colleagues published reference limits for plasma arginine and for the arginine-to-ADMA ratio. They found that the ratio was higher in people with better kidney function and lower in people with higher homocysteine and higher C-reactive protein, which links it to methylation status and inflammation.

This ratio helps explain a long-standing puzzle that researchers call the arginine paradox. Normal blood arginine is far higher than the amount the nitric oxide enzyme should need, yet extra arginine still seems to improve blood vessel function in some people. In a 2004 review, Böger explained that ADMA competes with arginine and that elevated ADMA may account for this paradox, which is why arginine is best interpreted next to ADMA rather than alone. My separate article on ADMA and SDMA covers the competitor side of this story in more detail, while this one focuses on arginine supply.

How are arginine levels connected to aging and root causes?

Arginine availability touches several processes that researchers connect with aging, starting with intercellular signaling. Nitric oxide is one of the main ways the lining of a blood vessel talks to the muscle around it, and when arginine is scarce or blocked that conversation gets quieter. Over time, a lining that makes less nitric oxide tends to become stiffer and more prone to inflammation.

The pathways that use up arginine matter just as much as the amount that is there. The enzyme arginase breaks arginine down to ornithine, and higher arginase activity leaves less arginine for nitric oxide. In laboratory work on human vascular smooth muscle cells and in mice, Xiong and colleagues found that arginase-II promoted mitochondrial dysfunction and cellular senescence in vessel wall cells, which they linked to features of unstable plaque. That research is early and comes from cell and animal models, so it hints at a mechanism rather than proving one in people.

Metabolism and nutrient sensing enter the picture too. In the LURIC study of more than 2,200 people having coronary angiography, Sourij and colleagues found that people with type 2 diabetes had a lower global arginine bioavailability ratio, and that a lower ratio tracked with markers of an inflamed, activated vessel lining. In a 2022 study using stable isotope tracers, Wierzchowska-McNew and colleagues found that adults with severe obesity had low-grade inflammation, lower plasma citrulline and lower production of new arginine, even though their blood sugar was normal.

From a root-cause perspective, I want to understand why arginine supply looks low. Protein intake and overall diet quality matter, since arginine comes from food and from the body’s own production from citrulline. Kidney function, chronic inflammation, blood sugar regulation, body weight, methylation status, smoking, sleep and ongoing stress can all shift the balance between arginine, its competitor ADMA and the enzymes that break it down. Genetics adds individual variation that we are only starting to understand.

What does the research show about arginine ratios and heart health?

Several cohort studies suggest that arginine ratios carry more information than arginine alone. In a 2009 study of 1,010 people having elective cardiac catheterization, Tang and colleagues found that a lower global arginine bioavailability ratio was associated with obstructive coronary artery disease and with a higher three-year risk of heart attack, stroke or death, while arginine levels by themselves were not, after adjustment. In the LURIC study, which followed patients for a median of 7.7 years, the lowest quarter of the ratio was associated with higher cardiovascular mortality. In a case-cohort study within the Mediterranean diet trial known as PREDIMED, Yu and colleagues found that a higher baseline arginine-to-ADMA ratio was associated with lower cardiovascular disease incidence, although one year of the Mediterranean diet did not change the ratio.

Supplement studies are a separate question. A 2019 review by Khalaf and colleagues found that both oral arginine and oral citrulline raise plasma arginine, with citrulline roughly twice as effective because less of it is broken down on the first pass through the gut and liver, and that arginine was associated with modest drops in blood pressure. Most of these studies are short, and the cohort findings above describe associations in people who were already at higher risk, so these ratios are best seen as research-stage markers that add context to a broader cardiovascular picture.

Related reading

If you would like to explore related topics, my articles on ADMA and SDMA, fibrinogen and the omega-3 index go deeper. You can also see the specialty tests I commonly recommend on my functional labs page.

Common questions about Arginine and the Arginine-to-ADMA Ratio

Why look at a ratio instead of arginine alone?

Arginine levels by themselves did not track heart outcomes well in some studies once other factors were considered. Comparing arginine with ADMA, or with ornithine and citrulline, shows how much of it is actually available for making nitric oxide.

What is the global arginine bioavailability ratio?

It is arginine divided by the sum of ornithine and citrulline, the products of the main pathways that use arginine up. A lower value suggests more arginine is being broken down relative to what is available.

Does citrulline raise arginine?

Research suggests that oral citrulline raises plasma arginine, and a 2019 review found it was roughly twice as effective as oral arginine because less of it is broken down on the first pass through the gut and liver.

Sources

This article is for educational purposes only and is not medical advice. It does not replace an individual evaluation. Talk with your healthcare provider before making changes to your diet, exercise, supplements, or medications, especially if you are pregnant, nursing, or managing a health condition.